WDNA.L
WisdomTree BioRevolution UCITS ETF - USD Acc
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 15.1 M
ASSETS UNDER MGMT
45 bp
EXPENSES
Fund Basics
| Inception date | Dec 03, 2021 |
| Regulation | UCITS |
| ISIN | IE000O8KMPM1 |
| Distributions | |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | No |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| TWIST BIOSCIENCE CORP. | 4.5 % |
| ELI LILLY & CO | 4.3 % |
| MODERNA, INC. | 3.2 % |
| JOHNSON & JOHNSON | 3.0 % |
| UNITED THERAPEUTICS CORP | 2.9 % |
| IMMUNOME, INC. | 2.7 % |
| STOKE THERAPEUTICS, INC. | 2.5 % |
| BEAM THERAPEUTICS, INC. | 2.4 % |
| DARLING INTERNATIONAL INC | 2.4 % |
| TEMPUS AI INC | 2.3 % |
Constituent Breakdown
| Number of holdings | 84 |
| Herfindahl-Hirschman Index | 184 |
| Wgt avg mkt cap (mns) | $80,620 |
| Large cap (>$10bn) | 49.9% |
| Mid cap ($2-10bn) | 17.6% |
| Small cap (<$2bn) | 24.5% |
| Developed mkts. | 96.0% |
| Emerging mkts. | 0.0% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 80.3 % |
 |
BRITAIN | 4.1 % |
 |
SWITZERLAND | 3.4 % |
 |
GERMANY | 3.3 % |
 |
DENMARK | 1.9 % |
 |
NETHERLANDS | 1.7 % |
 |
BELGIUM | 0.7 % |
 |
AUSTRALIA | 0.6 % |
Historical Performance
Standardized Performance (as of 05/31/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 8.6% | 56.0% | 10.2% | 4.6% | -- | -- | -- | -3.6% |
| Dividend Yield | 0.0% | 0.0% | 0.0% | 0.0% | -- | -- | -- | 0.0% |
| Total Returns | 8.6% | 56.0% | 10.2% | 4.6% | -- | -- | -- | -3.6% | Ann. Volatility | 25.5% | 27.2% | 26.1% | 25.3% | -- | -- | -- | 25.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 0.98 | 18% |
| MSCI EAFE | 0.78 | 18% |
| MSCI Emg Mkts | 0.60 | 19% |
Liquidity Measures
| Avg. volume (000) | 4 |
| ADV traded (mns) | $0 |
| Turnover | 0.6% |
| Avg. Bid/Ask (% of price) | 0.00% |
Technical Indicators
| 30d moving avg. (EMA) | $20.09 |
| Relative strength (RSI) | 55 |
| MACD/Signal | 0.06/-0.04 |
| Bollinger Bands (Upper/Lower) | $20.95/$19.15 |
| Short interest (% of AUM) | 0.0% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. WDNA.L |
Expenses vs. WDNA.L |
ALTAR Score™ vs. WDNA.L |
|---|---|---|---|---|
| GNOM.L | Global X Genomics & Biotechnology UCITs ETF | 35.9% | +5 bp | +0.4% |
| XDWH.DE | Xtrackers MSCI World Health Care UCITS ETF 1C | 26.2% | -20 bp | +10.2% |
| BTEC.L | iShares Nasdaq US Biotechnology UCITS ETF | 24.3% | -10 bp | +3.1% |
| BTEE.L | iShares Nasdaq US Biotechnology UCITS ETF | 24.3% | -10 bp | +3.1% |
| WHCA.L | iShares MSCI World Health Care Sector Advanced UCITS ETF | 23.5% | -27 bp | +9.8% |
| WHCS.AS | iShares MSCI World Health Care Sector Advanced UCITS ETF | 23.5% | -27 bp | +9.9% |
| HEAL.L | iShares Healthcare Innovation UCITS ETF | 23.2% | -5 bp | +5.8% |
| XGEN.DE | Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C | 23.2% | -15 bp | +3.6% |
| XUHC.DE | Xtrackers MSCI USA Health Care UCITS ETF 1D | 20.7% | -33 bp | +10.1% |
| XUHL.DE | Xtrackers MSCI USA Health Care UCITS ETF 1C | 20.7% | -33 bp | +10.5% |
Risk and Returns: WDNA.L vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 6/16/2026
Peer Group Comparison
Sample data. Subscribe for access.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-3.3%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 727 funds in the Global Equity category with an average
ALTAR Score™ of 4.3% and a standard deviation
of 2.6%. WDNA.L's ALTAR Score™ is approximately -2.9 standard
deviations above the category average. This places WDNA.L in the 1st percentile
among funds in the category.
Sell-Side Consensus
$24.87
PRICE TARGET
+20.6%
UPSIDE